For the impact of PPM1D in therapy-related AML and MDS, mutation of such often led to truncation of the PPM1D protein, which can no longer suppress p53, thereby evading cell death during chemotherapy [75,79]. This evidence concerns the gene PPM1D and myelodysplastic syndrome.